Advertisement

Guideline-Based Management of Non-muscle Invasive Bladder Cancer: Comparison of the AUA, EAU, ICUD, and NCCN Guidelines

  • Jeffrey C. Bassett
  • John D. Seigne
  • Peter E. ClarkEmail author
Chapter

Abstract

A number of evidence-based guidelines exist for the management of non-muscle invasive bladder cancer (NMIBC), including those published by the American Urological Association (AUA), the European Association of Urology (EAU), the International Consultation on Urological Disease (ICUD), and National Comprehensive Cancer Network (NCCN). These guidelines serve to equip the clinician with an evidence base for treatment decisions at various points in the clinicopathologic course, of import given the complexity of managing a neoplasm with a high likelihood of recurrence and progression. Herein we detail the methodology utilized in the creation of the aforementioned guidelines, noting the similarities and differences in the panels’ approach. We apply the AUA, EAU, ICUD, and NCCN guidelines to specific clinical vignettes oft encountered in the management of NMIBC, highlighting where consensus and dissensus exist. Finally, we discuss the strengths and limitations of guideline-based management, in particular the ability of guidelines to account for clinically relevant variables such as patient age, preferences, and response to treatment.

Keywords

Bladder cancer Non-(muscle) invasive Urothelial cell carcinoma Practice guidelines American Urological Association European Association of Urology International Consultation on Urological Disease National Comprehensive Cancer Network 

References

  1. 1.
    Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update. American Urological Association. Accessed April 14, 2013, at https://www.auanet.org/education/guidelines/bladder-cancer.cfm
  2. 2.
    Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). European Assoication of Urology (EAU). Accessed April 14, 2013, at http://www.uroweb.org/guidelines/online-guidelines/
  3. 3.
    International Consultation on Urological Diseases (ICUD). Bladder cancer, 2nd edn. Accessed June 3, 2013, at http://www.icud.info/bladdercancer2nd.html
  4. 4.
    National Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder cancer. Version 1. 2013. Accessed May 1st, 2013, at http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
  5. 5.
    Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol Esp. 2012;36:389–402.PubMedCrossRefGoogle Scholar
  7. 7.
    Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:36–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Oxford Centre for Evidence-based Medicine Levels of Evidence. March 2009. Accessed May 2013, at http://www.cebm.net/index.aspx?0=1025
  9. 9.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–5. discussion 75–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Rodriguez F, Palou J, Martinez R, et al. Practical guideline for the management of adverse events associated with BCG installations. Arch Esp Urol. 2008;61:591–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl. 2008;7:667–74.CrossRefGoogle Scholar
  13. 13.
    Dahm P, Chapple CR, Konety BR, et al. The future of clinical practice guidelines in urology. Eur Urol. 2011;60:72–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jeffrey C. Bassett
    • 1
  • John D. Seigne
    • 2
  • Peter E. Clark
    • 3
    Email author
  1. 1.Department of UrologyKaiser Permanente Southern CaliforniaAnaheimUSA
  2. 2.Division of Urology, Dartmouth-Hitchcock Medical CenterNorris Cotton Cancer CenterLebanonUSA
  3. 3.Vanderbilt University Medical CenterNashvilleUSA

Personalised recommendations